Collage photo of Megan E. Tesch and Ann Partridge
May 6, 2025, 17:21
Megan E. Tesch: Improving Endocrine Therapy Adherence in Breast Cancer
Megan E. Tesch, Breast Medical Oncologist at Dana-Farber Cancer Institute, shared a post on X about a paper she and Ann Partridge co-authored published in Journal of Clinical Oncology:
“Premature discontinuation of adjuvant Endocrine Therapy is common in early breast cancer – Ann Partridge and I discuss the study by Dumas et al. modelling the potential survival benefits of improved ET persistence, particularly for young adults with breast cancer.”
Title: Can Improving Adjuvant Endocrine Therapy Persistence Improve Survival Outcomes for Patients With Early-Stage Breast Cancer?
Authors: Megan E. Tesch and Ann Partridge
Read the Full Article on Journal of Clinical Oncology.
More posts featuring Megan E. Tesch.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 6, 2025, 17:21
May 6, 2025, 16:17
May 6, 2025, 16:09